Patents by Inventor Xitao Li

Xitao Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK3 selective inhibitor
    Patent number: 11578060
    Abstract: The present invention relates to a compound of Formula (I)/(II) or pharmaceutically acceptable salts thereof. In Formula (I), Rh, Rg, Rf, m, Re, Rd, Ra, Rb, and Rc are as defined in the description. The present invention further relates to a pharmaceutical composition comprising the compound of Formula (I)/(II) or pharmaceutically acceptable salts thereof, and use of the compound of Formula (I)/(II) or the pharmaceutical composition in the manufacture of a medicament for treating inflammations such as rheumatoid arthritis.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: February 14, 2023
    Assignee: PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL
    Inventors: Zhengying Pan, Liyang Shi, Xitao Li
  • INHIBITOR OF BRUTON TYROSINE KINASE
    Publication number: 20220017484
    Abstract: Disclosed herein is a compound of Formula (I) with a Btk inhibitory activity, wherein all the variables are as defined herein. The compound can be used for the treatment of diseases such as autoimmune diseases, xenogeneic immune diseases, cancers or thromboembolic diseases. Also disclosed is a pharmaceutical composition comprising a compound of Formula (I). Further provided is a compound capable of inhibiting the activity of Bruton's tyrosine kinase by covalent binding.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 20, 2022
    Inventors: Zhengying Pan, Zhaodong Jiao, Xitao Li, Guanyu Tao, Yanxia Shi, Rui Zhang
  • JAK3 SELECTIVE INHIBITOR
    Publication number: 20210214344
    Abstract: The present invention relates to a compound of Formula (I)/(II) or pharmaceutically acceptable salts thereof. In Formula (I), Rh, Rg, Rf, m, Re, Rd, Ra, Rb, and Rc are as defined in the description. The present invention further relates to a pharmaceutical composition comprising the compound of Formula (I)/(II) or pharmaceutically acceptable salts thereof, and use of the compound of Formula (I)/(II) or the pharmaceutical composition in the manufacture of a medicament for treating inflammations such as rheumatoid arthritis.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 15, 2021
    Inventors: Zhengying PAN, Liyang SHI, Xitao LI
  • Kinase inhibitor and method for treatment of related diseases
    Patent number: 9782406
    Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: October 10, 2017
    Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co., Ltd.
    Inventors: Zhengying Pan, Xitao Li
  • KINASE INHIBITOR AND METHOD FOR TREATMENT OF RELATED DISEASES
    Publication number: 20150352109
    Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
    Type: Application
    Filed: August 19, 2015
    Publication date: December 10, 2015
    Inventors: Zhengying PAN, Xitao LI
  • Kinase inhibitor and method for treatment of related diseases
    Patent number: 9150522
    Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: October 6, 2015
    Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co. Ltd.
    Inventors: Zhengying Pan, Xitao Li